ProMIS Neurosciences Inc. (PMN) - Total Liabilities
Based on the latest financial reports, ProMIS Neurosciences Inc. (PMN) has total liabilities worth $12.27 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of ProMIS Neurosciences Inc. to track the company's year-over-year net asset growth rate.
ProMIS Neurosciences Inc. - Total Liabilities Trend (2005–2024)
This chart illustrates how ProMIS Neurosciences Inc.'s total liabilities have evolved over time, based on quarterly financial data. See ProMIS Neurosciences Inc. (PMN) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
ProMIS Neurosciences Inc. Competitors by Total Liabilities
The table below lists competitors of ProMIS Neurosciences Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Varengold Bank AG
F:VG8
|
Germany | €1.03 Billion |
|
Mepet Metro Petrol ve Tesisleri Sanayi Ticaret AS
IS:MEPET
|
Turkey | TL529.31 Million |
|
Pacific Booker Minerals Inc.
V:BKM
|
Canada | CA$1.22 Million |
|
US Global Investors Inc
NASDAQ:GROW
|
USA | $2.87 Million |
|
Amanah Leasing Public Company Limited
BK:AMANAH
|
Thailand | ฿2.38 Billion |
|
Crown Crafts Inc
NASDAQ:CRWS
|
USA | $36.91 Million |
|
Cayman Tung Ling Co Ltd
TWO:2924
|
Taiwan | NT$485.00 Million |
|
DLP Resources Inc
V:DLP
|
Canada | CA$193.41K |
Liability Composition Analysis (2005–2024)
This chart breaks down ProMIS Neurosciences Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of ProMIS Neurosciences Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProMIS Neurosciences Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProMIS Neurosciences Inc. (2005–2024)
The table below shows the annual total liabilities of ProMIS Neurosciences Inc. from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.42 Million | -75.44% |
| 2023-12-31 | $9.87 Million | -11.92% |
| 2022-12-31 | $11.20 Million | -26.72% |
| 2021-12-31 | $15.28 Million | +536.62% |
| 2020-12-31 | $2.40 Million | +43.29% |
| 2019-12-31 | $1.68 Million | -7.42% |
| 2018-12-31 | $1.81 Million | +183.90% |
| 2017-12-31 | $637.45K | -29.05% |
| 2016-12-31 | $898.39K | +63.12% |
| 2015-12-31 | $550.76K | +11.77% |
| 2013-12-31 | $492.77K | -6.82% |
| 2012-12-31 | $528.83K | -1.72% |
| 2011-12-31 | $538.06K | +110875.99% |
| 2010-12-31 | $484.84 | -99.92% |
| 2009-12-31 | $634.39K | +34.40% |
| 2008-12-31 | $472.01K | -62.49% |
| 2007-12-31 | $1.26 Million | +118.81% |
| 2006-12-31 | $575.14K | +170.50% |
| 2005-12-31 | $212.62K | -- |
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product c… Read more